Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor

被引:10
|
作者
Wooten, Catherine J. [1 ]
Adcock, Audrey F. [1 ]
Agina-Obu, DaTonye I. [1 ]
Lopez, Dayami [1 ]
机构
[1] N Carolina Cent Univ, Coll Arts & Sci, BR1TE, Dept Pharmaceut Sci, Durham, NC 27707 USA
关键词
LDL receptor; LDL; PCSK9; IDOL; Human hepatocyte-like C3A cells; DENSITY-LIPOPROTEIN RECEPTOR; CONVERTASE SUBTILISIN/KEXIN TYPE-9; HEPATOCELLULAR-CARCINOMA; CHOLESTEROL REDUCTION; MONOCLONAL-ANTIBODY; SQUALENE SYNTHASE; ANNEXIN A2; DEGRADATION; INHIBITION; STATINS;
D O I
10.1016/j.abb.2014.01.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin/kexin-9 (PCSK9) acts mainly by forming complexes with the LDL receptor at the cell surface, which are then degraded in the lysosome. Studies were performed to determine whether excess levels of PCSK9 was sufficient to induce PCSK9/LDL receptor complex formation in human hepatocyte-like C3A cells. It was demonstrated using ELISA that instead of considering the overall levels of PCSK9 protein that is produced in response to certain treatment, what is critical is how much PCSK9 is actually capable of forming complexes. Despite the high levels, most of the PCSK9 produced as a result of incubating cells with a medium supplemented with BD (TM) MITO+ serum extender (MITO+ medium) appeared to be inhibited by a secreted factor. Having lower levels of PCSK9/LDL receptor complexes did not prevent an increase in the degradation rate of LDL receptors in MITO+ medium as compared to fetal bovine serum (FBS) containing medium (Regular medium), an effect that did not correlate with an increase in protein levels of the inducible degrader of LDL receptors (IDOL), as demonstrated using Western blotting analysis. Additional studies are required to determine the exact mechanism(s) for the degradation of the LDL receptor and/or to identify the secreted inhibitor of PCSK9. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:124 / 132
页数:9
相关论文
共 50 条
  • [1] Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor (vol 545, pg 124, 2014)
    Wooten, Catherine J.
    Adcock, Audrey F.
    Agina-Obu, DaTonye I.
    Lopez, Dayami
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2014, 562 : 122 - 122
  • [2] BINDING OF PCSK9 TO CIRCULATING LDL: EFFECT OF PCSK9 MONOCLONAL ANTIBODIES ON THE LDL-BOUND PCSK9?
    De Stefano, D.
    Baragetti, A.
    Baragetti, A.
    Macri, N.
    Tavori, H.
    Fazio, S.
    Catapano, A. L.
    ATHEROSCLEROSIS, 2018, 275 : E101 - E101
  • [3] Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
    Shapiro, Michael D.
    Tavori, Hagai
    Oleaga, Carlota
    Miles, Joshua
    Fazio, Sergio
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [4] New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide
    Landmesser, Ulf
    Makhmudova, Umidakhon
    CIRCULATION, 2023, 148 (02) : 159 - 161
  • [5] EFFECTS OF PCSK9 VARIANTS AND PCSK9 LEVELS ON RISK OF ISCHEMIC STROKE
    Chen, W.
    Pan, Y.
    Wang, Y.
    Li, H.
    Meng, X.
    Wang, Y.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 629 - 629
  • [6] Molecular basis for LDL receptor recognition by PCSK9
    Kwon, Hyock Joo
    Lagace, Thomas A.
    McNutt, Markey C.
    Horton, Jay D.
    Deisenhofer, Johann
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (06) : 1820 - 1825
  • [7] PCSK9 and atherosclerosis: beyond LDL
    Catapano, A. L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 28 - 28
  • [8] PCSK9 inhibitors for LDL lowering
    Walsh, Lames P.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (07) : 575 - 577
  • [9] Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
    Holla, Oystein L.
    Cameron, Jamie
    Berge, Knut Erik
    Ranheim, Trine
    Leren, Trond P.
    BMC CELL BIOLOGY, 2007, 8 (1)
  • [10] Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
    Øystein L Holla
    Jamie Cameron
    Knut Erik Berge
    Trine Ranheim
    Trond P Leren
    BMC Cell Biology, 8